title: Antimitotic inhibitors.
abstract: Of the agents available in the treatment of both solid and hematologic cancers, microtubule-targeted agents are among the most widely used and exploiting other mechanisms involving the microtubule and its role in mitosis is an area of continued interest. This review will focus on novel microtubule-targeted agents, both recently approved (eg, ixabepilone and eribulin) and in later-stage clinical trials, and kinase inhibitors that aim to directly inhibit the mitotic spindle, such as the aurora kinase, pololike kinase, and kinsein-spindle protein inhibitors.
authors.affiliation: Program in Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Susana M
authors.initials: SM
authors.lastname: Campos
authors.forename: Don S
authors.initials: DS
authors.lastname: Dizon
mesh_terms: D050256:Antimitotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D064127:Aurora Kinases; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D016547:Kinesins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D050257:Tubulin Modulators / Q000494:pharmacology* / Q000627:therapeutic use; D000097869:Polo-Like Kinase 1
chemical_list: D050256:Antimitotic Agents; D064127:Aurora Kinases; D018797:Cell Cycle Proteins; D016547:Kinesins; D047428:Protein Kinase Inhibitors; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D050257:Tubulin Modulators; D000097869:Polo-Like Kinase 1